Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by LVW Advisors LLC

LVW Advisors LLC lowered its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL) by 11.8% in the fourth quarter, HoldingsChannel reports. The fund owned 3,058 shares of the medical research company’s stock after selling 410 shares during the quarter. LVW Advisors LLC’s holdings in Charles River Laboratories International were worth $565,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. American Century Companies Inc. increased its stake in Charles River Laboratories International by 4.6% during the second quarter. American Century Companies Inc. now owns 6,556 shares of the medical research company’s stock worth $1,354,000 after acquiring an additional 291 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Charles River Laboratories International by 20.0% during the 2nd quarter. Dimensional Fund Advisors LP now owns 561,075 shares of the medical research company’s stock worth $115,912,000 after purchasing an additional 93,682 shares during the period. Mercer Global Advisors Inc. ADV increased its position in Charles River Laboratories International by 74.5% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 4,031 shares of the medical research company’s stock worth $833,000 after purchasing an additional 1,721 shares in the last quarter. Amalgamated Bank boosted its position in shares of Charles River Laboratories International by 21.7% in the second quarter. Amalgamated Bank now owns 13,036 shares of the medical research company’s stock worth $2,693,000 after buying an additional 2,323 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new stake in Charles River Laboratories International in the second quarter valued at approximately $124,000. 98.91% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have commented on CRL. UBS Group reiterated a “neutral” rating and issued a $185.00 price objective (down previously from $250.00) on shares of Charles River Laboratories International in a report on Friday. Citigroup lowered Charles River Laboratories International from a “neutral” rating to a “sell” rating and lowered their price objective for the company from $215.00 to $175.00 in a research note on Tuesday, October 1st. William Blair reaffirmed an “outperform” rating on shares of Charles River Laboratories International in a research report on Tuesday, January 14th. StockNews.com lowered shares of Charles River Laboratories International from a “buy” rating to a “hold” rating in a research note on Thursday, November 7th. Finally, TD Cowen increased their price objective on shares of Charles River Laboratories International from $203.00 to $227.00 and gave the company a “hold” rating in a research note on Monday, November 11th. Three equities research analysts have rated the stock with a sell rating, twelve have assigned a hold rating and two have given a buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $209.00.

Insider Buying and Selling

In other news, Director Richard F. Wallman sold 6,621 shares of the stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $216.12, for a total value of $1,430,930.52. Following the completion of the transaction, the director now owns 12,386 shares of the company’s stock, valued at approximately $2,676,862.32. This represents a 34.83 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Performance

Shares of CRL opened at $163.77 on Tuesday. The firm has a fifty day moving average of $189.50 and a 200-day moving average of $198.14. The company has a market cap of $8.37 billion, a price-to-earnings ratio of 20.50, a price-to-earnings-growth ratio of 6.62 and a beta of 1.38. The company has a debt-to-equity ratio of 0.61, a quick ratio of 1.14 and a current ratio of 1.48. Charles River Laboratories International, Inc. has a 1 year low of $160.85 and a 1 year high of $275.00.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, November 6th. The medical research company reported $2.59 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.43 by $0.16. Charles River Laboratories International had a net margin of 10.44% and a return on equity of 14.29%. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $975.99 million. During the same period in the previous year, the business posted $2.72 EPS. Charles River Laboratories International’s revenue was down 1.6% on a year-over-year basis. As a group, equities analysts anticipate that Charles River Laboratories International, Inc. will post 10.18 earnings per share for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).